Moscow, Moscow City, Russia, March 2026 – Arijit Das has stepped into the role of HR Head – Russia at Dr. Reddy’s Laboratories, based in Moscow, marking a significant international leadership transition within the organization.
Arijit moves into this role after serving as Group HR Head – APAC, Emerging Markets HO & Innovative Assets at Dr. Reddy’s, where he partnered with regional and global leadership teams to align people strategy with business growth priorities. His elevation to lead HR for the Russia market reflects the organization’s confidence in his ability to drive performance, strengthen capability, and support expansion in one of its key international markets.
Prior to his recent tenure at Dr. Reddy’s, Arijit spent over three years at Mondelēz International, where he served as People Lead (Sales) across North, East, Bangladesh, and Nepal, partnering with commercial leadership to drive talent strategy, sales capability building, and organizational effectiveness across complex geographies.
Earlier, he held multiple progressive HR leadership roles at Cipla, including Associate Director & Head HR – Alternate Channels & Super Speciality Cluster and various HRBP mandates across East, North, and South India. His responsibilities spanned large-scale sales teams, oncology and critical care businesses, total rewards, global compensation & mobility, and talent management for multi-state operations.
Arijit’s career foundation was built through structured leadership development assignments at Aditya Birla Group and Hindalco Industries Limited, where he worked across talent management, organizational development, HRIS, and contract labour management initiatives. He also gained early exposure to HR transformation projects at organizations including ITC Limited and Reliance. He holds an MBA from XLRI Jamshedpur.
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories, established in 1984 and headquartered in Hyderabad, India, is a global pharmaceutical company driven by its purpose of “Good Health Can’t Wait.” The company offers a broad portfolio including APIs, generics, branded generics, biosimilars, and OTC products.
With major markets spanning the USA, India, Russia & CIS countries, China, Brazil, and Europe, Dr. Reddy’s continues to invest in innovation, digital therapeutics, consumer healthcare, and ESG-led growth, reinforcing its commitment to access, affordability, and sustainability.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
